<DOC>
	<DOCNO>NCT02462473</DOCNO>
	<brief_summary>The purpose study determine number Medication Treatment Modifications ( MTMs ) make clinician every visit antipsychotic medication plasma level ( AMPL ) result available compare AMPL result available .</brief_summary>
	<brief_title>A Study Assess Clinical Utility Antipsychotic Medication Levels Plasma Determined Liquid Chromatography-Tandem Mass Spectrometry</brief_title>
	<detailed_description>This naturalistic , open-label ( people know identity intervention ) , multicenter ( one hospital medical school team work medical research study ) , pilot clinical utility study sequential parallel cohort design participant diagnosis schizophrenia schizoaffective disorder . The study consist 3 Phases : Screening Phase ( Screening first assessment visit preferably take place day ) , active assessment phase ( 12 week , An optional 12 week extension phase . Participants assign Cohort 1 , randomize Cohort 2 Cohort 3 . Participants cohorts 2 3 receiving long act injectable ( LAI ) formulation paliperidone and/or risperidone complete participation active assessment phase ) option continue extension phase . The duration study participation approximately 12 week . Participants optional extension phase additional 12 week study participation . The primary outcome measure number Medication Treatment Modifications ( MTMs ) make clinician every visit . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Participant diagnosis schizophrenia ( Code 295.90 ) schizoaffective disorder ( Code 295.70 ) accord Diagnostic Statistical Manual Mental Disorders , 5th edition ( DSM 5 ) , base history clinical assessment investigator Participant current active medication management issue experience medication treatment modification within 6 week prior Screening Participant currently take one follow antipsychotic medication least 1 week oral antipsychotic least 1 injection cycle longacting injectable ( LAI ) antipsychotic . In addition , treat clinician plan continue antipsychotic medication ( ) least 4 week subsequent Screening visit . Participant may take one formulation particular medication ( oral LAI ) minimum dose specify protocol . Qualifying formulation antipsychotic medication : Aripiprazole ( oral formulation ) , Olanzapine ( oral formulation ) , Paliperidone ( oral and/or LAI formulation ) , Quetiapine ( oral formulation ) , Risperidone ( oral and/or LAI formulation ) Participant clinically significant suicidal behavior ideation week prior Screening , accord investigator 's judgment Participant generally healthy clinically significant unstable medical problem determine investigator , except indication antipsychotic treatment prescribe . This determination must record participant 's source document initial investigator Participant attend outpatient psychiatric clinic 12 month since last psychiatric hospitalization During Screening , participant active alcohol substance use disorder ( except tobacco ) moderate severe severity accord DSM 5 criterion Participant history currently clinically significant ( particularly unstable ) medical illness , indication participant take antipsychotic therapy , investigator considers exclude participant could interfere participant complete study interpretation study result . Treated , stable , chronic medical problem allow , long condition interfere study assessment Participant receive clozapine Participant donate blood blood product substantial loss blood ( ie , blood loss approximately 450 milliliter ( mL ) blood loss require blood transfusion ) within 1 month Screening intention donate blood blood product study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Liquid Chromatography-Tandem Mass Spectrometry</keyword>
</DOC>